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Objectives: Aneurysmal subarachnoid hemorrhage often leads 
to death and poor clinical outcome. Injury occurring during the 
first 72 hours is termed “early brain injury,” with disruption of the 
nitric oxide pathway playing an important pathophysiologic role in 
its development. Quantitative electroencephalographic variables, 
such as α/δ frequency ratio, are surrogate markers of cerebral 
ischemia. This study assessed the quantitative electroencepha-
lographic response to a cerebral nitric oxide donor (intravenous 
sodium nitrite) to explore whether this correlates with the eventual 
development of delayed cerebral ischemia.
Design: Unblinded pilot study testing response to drug intervention.
Setting: Neuroscience ICU, John Radcliffe Hospital, Oxford, 
United Kingdom.
Patients: Fourteen World Federation of Neurosurgeons grades 3, 
4, and 5 patients (mean age, 52.8 yr [range, 41–69 yr]; 11 women).
Interventions: IV sodium nitrite (10 μg/kg/min) for 1 hour.
Measurements and Main Results: Continuous electroencepha-
lographic recording for 2 hours. The alpha/delta frequency ratio 
was measured before and during IV sodium nitrite infusion. Seven 
of 14 patients developed delayed cerebral ischemia. There was a 
+30% to +118% (range) increase in the alpha/delta frequency 
ratio in patients who did not develop delayed cerebral ischemia 
(p < 0.0001) but an overall decrease in the alpha/delta frequency 
ratio in those patients who did develop delayed cerebral isch-
emia (range, +11% to –31%) (p = 0.006, multivariate analysis 
accounting for major confounds).
Conclusions: Administration of sodium nitrite after severe sub-
arachnoid hemorrhage differentially influences quantitative 
electroencephalographic variables depending on the patient’s 
susceptibility to development of delayed cerebral ischemia. With 
further validation in a larger sample size, this response may be 
developed as a tool for risk stratification after aneurysmal sub-
arachnoid hemorrhage. (Crit Care Med 2016; XX:00–00)
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Subarachnoid hemorrhage (SAH) is usually caused by rupture of a cerebral aneurysm located in the circle of Willis (1). It disproportionately affects a younger popu-
lation (2) and is often fatal. The main mechanisms of brain 
injury after SAH include early brain injury (EBI), which occurs 
in the first 72 hours following ictus, and delayed cerebral isch-
emia (DCI), in 30% of patients unpredictably 3–14 days later 
(3). It is difficult to predict the evolution of cerebral injury fol-
lowing SAH using currently available methods. Clinical scoring 
systems have poor accuracy, and bedside clinical monitoring 
requires specialist interpretation.
The focus of SAH research has been to investigate the 
mechanisms behind DCI, as this remains the most important 
cause of morbidity and mortality in patients who survive ini-
tial aneurysm rupture (4). Historically, DCI was attributed to 
spasm of the cerebral blood vessels; however, the relationship 
between angiographic evidence of vessel spasm and DCI is 
weak (5, 6). In addition, treatment of cerebral arterial vasocon-
striction does not improve clinical outcome (7). There is now 
a growing body of evidence suggesting that changes occurring 
during EBI set the scene for the development of DCI (3, 7). An 
improved understanding and measurement of the processes 
associated with EBI could offer an opportunity to better pre-
dict DCI and improve patient outcomes (8).
Emerging evidence suggests that disruption to the nitric 
oxide (NO) signaling pathway may play a critical role in EBI 
(9–11). Endogenous NO has been proposed to exert a protec-
tive action after brain injury through a number of different 
pathways, including promoting cerebral blood flow, attenuat-
ing mitochondrial damage, and preventing cellular apoptosis 
(12). Following SAH, the integrity of these pathways becomes 
disrupted, resulting in a cascade of cellular injury resulting in 
cell death (13). The level of disruption of the NO signaling 
pathways has been shown to correlate with eventual outcome 
after SAH (10).
Sodium nitrite (a prodrug) is suited as an exogenous NO 
donor in SAH patients because it is converted to NO under 
conditions of hypoxia or acidosis. As sodium nitrite has a rela-
tively rapid onset of action, its effects are measurable in a brief 
time frame and, when combined with a measurement of cere-
bral injury, it may represent an ideal drug probe of EBI severity.
Quantitative electroencephalography (qEEG) uses power 
spectral analysis to obtain measures of the different compo-
nents of the electroencephalography, sensitively detecting 
disturbed neuronal activity during the development of isch-
emia (14). SAH results in a variety of abnormalities in qEEG 
variables, specifically decreases in the alpha/delta frequency 
ratio (ADR), and a decrease in relative alpha power variabil-
ity (15–18). These patterns have been shown to correlate with 
subsequent cerebral ischemia (19).
Based on the evidence that disruption of the cerebral NO 
pathway is a main driver of the pathophysiologic processes 
occurring during EBI, we hypothesized that the qEEG response 
to a sodium nitrite, an NO donor, could be used as a dynamic 
probe of EBI severity and that this response would be linked to 
the subsequent development of DCI.
MATERIALS AND METHODS
Patients 18–80 years old admitted to the neuroscience ICU 
(NICU) at the John Radcliffe Hospital, Oxford, after having 
suffered severe aneurysmal SAH (World Federation of Neuro-
surgeons [WFNS] grade 3, 4, or 5 at the time of presentation) 
were eligible for inclusion in the study. No patient showed clin-
ical evidence of DCI or angiographic cerebral arterial constric-
tion at the time of the study.
Written informed consent was obtained from the next of 
kin of all participants and from participants if they regained 
capacity to consent. The study was approved by the South 
Central—Oxford C NHS Health Research Authority Ethics 
Committee 12/SC/0366. Exclusion criteria included contrain-
dications to sodium nitrite, specifically severe cardiovascular 
compromise and preexisting methemoglobinemia. Next of kin 
provided information regarding smoking, medication, hyper-
tension, and family history.
All patients underwent standard clinical care that was not 
influenced by inclusion in this study. All were given nimodip-
ine for 14 days. Computed tomography (CT) of the brain was 
performed in the event of lack of wakening in sedated patients 
or worsening of neurologic signs in awake patients, according 
to the clinical policy of the neuro-ICU. Patients who did not 
demonstrate neurologic deterioration did not undergo CT 
scanning in the acute period; however, they did later receive 
follow-up brain magnetic resonance imaging at 6 months as 
per local protocol, which confirmed the lack of new infarction.
DCI was diagnosed based on consensus guidelines (20). 
In those patients who remained intubated and sedated, this 
was done by CT. Two patients (patients 2 and 4) had treat-
ment withdrawn and subsequently died after CT evidence of 
widespread infarction secondary to DCI. The study investiga-
tors were not responsible for the clinical care of these patients. 
Treatment of DCI was via a standardized protocol involving 
hypertension, maintenance of euvolemia, and maintenance of 
a hemoglobin level above 8 g/dL.
Study Design
Electroencephalography. Following definitive endovascular 
aneurysm treatment, each patient underwent a 2-hour period 
of continuous electroencephalographic monitoring (Porti 7 
system, Twente Medical Systems International, Oldenzaal, The 
Netherlands) on one occasion, as soon as possible after endo-
vascular securing of the aneurysm. We used a simplified electro-
encephalographic montage (16), a compromise between stable 
maintenance of recording and full coverage of all vascular terri-
tories. Seven to 13 unipolar electroencephalographic electrodes 
were used at the following positions defined according to the 
international 10–20 system: Cz, Fz, Pz, Fp1, Fp2, F3, F4, P3, P4, 
T3, T4, O1, and O2. Electroencephalographic data were digitized 
at a sampling rate of 2,048 Hz, with a high pass filter of 0.5 Hz 
and a low pass filter of 30 Hz.
Sodium Nitrite Infusion. An infusion of sodium nitrite 
at 10 μg/kg/min was commenced at the start of the second 
hour of electroencephalographic recording and continued for 
1 hour. The dosing schedule was developed as a compromise 
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between ensuring adequate delivery of cerebral NO and mini-
mization of cardiovascular effects. Changes in infusion rates of 
sedative drug levels and vasopressors were minimized for the 
duration of the recording.
Physiologic Measurements. Participants underwent simul-
taneous transcranial Doppler (TCD) monitoring. Insonation 
of the middle cerebral artery (MCA) M1 segment was per-
formed unilaterally on the side with the best window using 
color-coded duplex ultrasound (EZ-Dop, DWL; 2-Mz probe; 
EZ-Dop GmbH, Singen, Germany). End-tidal Co
2
, end-tidal 
O
2
, arterial blood pressure, and pulse oximetry were recorded 
continuously and collected on a Power-1401 data acquisition 
interface (Cambridge Electronic Design, Cambridge, UK). 
Arterial Co
2
 values were collected once during the duration of 
the recording as part of routine clinical care. Missing values are 
as follows: patient 10 did not have an adequate TCD window 
and we were unable to record the intracranial pressure (ICP) 
waveform for patients 1 and 13 and end-tidal gases in patient 7.
Follow-Up. Each surviving patient was followed up at 3–6 
months post rupture. Telephone follow-up was performed 
for patients who were unable to attend hospital. Primary out-
come was defined as the presence or absence of DCI. Second-
ary outcome was assessed by modified Rankin scale (21) at 
3 months, via structured standardized questions in person or 
by telephone.
Quantitative Electroencephalographic Analysis
Preprocessing was carried out using custom-written MAT-
LAB (MathWorks, Natick, MA) code and the EEGLAB version 
13.4.3b analysis toolbox (EEGLAB, San Diego, CA) (22). Data-
sets were rereferenced to the average of mastoid reference elec-
trodes and band pass filtered from 0.5 to 15 Hz using a linear 
finite impulse response filter. Each electroencephalographic 
recording was visually inspected, and artifacts were manually 
removed.
Spectral analysis was carried out using FieldTrip (23), a 
MATLAB software toolbox for electroencephalographic analy-
sis. Data were windowed into 30-second segments that over-
lapped by 50%. Time-frequency analysis was performed using 
a multitaper spectral estimation using discrete prolate spheroi-
dal (Slepian) sequences with 14 tapers and fast Fourier trans-
form algorithm for each electrode channel. Five 60-second 
epochs were selected randomly from the first (baseline) and 
last 30 minutes of the recording (during infusion). The epochs 
were separated by at least 60 seconds to avoid autocorrelation. 
The corresponding frequency distribution in each epoch was 
identified, which enabled determination of power values in the 
following frequency bands: delta, 1–4 Hz; alpha, 8–12 Hz; and 
total low frequency power, 1–15 Hz.
Two multivariate analyses were used to investigate the effects of 
sodium nitrite on ADR, including potential confounding factors 
as covariates (age, propofol, midazolam, and WFNS grade, using 
the R statistical package; R Foundation for Statistical Computing, 
Vienna, Austria). The square root of the ADR ( ADR) was 
used as the response variable to achieve the required normality 
and homoscedasticity in the residuals. The goodness of fit was 
assessed via Shapiro-Wilk normality tests on fixed and random 
effect residuals and by calculation of correlation coefficient (R2).
A multilevel linear regression model incorporated both base-
line ADR and the ADR response to sodium nitrite as response 
variables. This model takes into account the repeated measures 
taken on each patient. A second model incorporated baseline 
ADR  as a covariate, with the ADR response to sodium nitrite 
as a response. This model used a Bayesian approach, allowing 
the baseline ADR  to be incorporated as a normally distrib-
uted random variable. This enabled direct investigation of the 
effect of sodium nitrite on the baseline ADR  and allowed us 
to explore whether the dependence of the sodium nitrite effect 
on baseline ADR  for patients who did not develop DCI dif-
fered significantly from those that subsequently developed DCI. 
Further description of these approaches can be found in the 
supplementary information (Supplemental Digital Content 1, 
http://links.lww.com/CCM/B945).
Physiologic Data Analysis
Waveform analysis was performed using custom-written 
MATLAB code, enabling calculation of average baseline and 
nitrite infusion values for TCD MCA velocity (MCAV), arte-
rial blood pressure, end-tidal Co
2
, end-tidal O
2
, and ICP. Values 
were compared for each subject using paired t tests. p values 
less than 0.05 were considered significant.
Sample Size Calculation
As a study such as this has not been performed before, a 
formal power calculation was not possible. We anticipated 
a powerful effect on electroencephalographic power based 
on a previous resting electroencephalographic study, which 
showed a 24% lower ADR in nine patients who developed 
DCI (15). Animal studies have demonstrated that sodium 
nitrite seems to have a strong effect on the subsequent 
development of ischemia (24). We therefore expected 10–14 
patients to demonstrate enough change to allow an effect of 
the drug to be detected.
RESULTS
Demographics, Treatment and Clinical Outcomes
Fourteen patients (mean age, 52.8 yr [range, 41–69 yr]; 11 women) 
with spontaneous SAH successfully treated with endovascular 
coiling were recruited over a total study period of 13 months. All 
patients admitted to the NICU at the John Radcliffe Hospital were 
eligible for inclusion in the study.
All patients had modified Fisher grade 4 (thick SAH with 
intraventricular hemorrhage) and WFNS grades 3–5 on initial 
presentation. The WFNS grade 3 patients (patients 5, 7, 9, 10, 
and 12) were sedated and intubated either because of a subse-
quent drop in their Glasgow Coma Score secondary to seizures 
or subsequent episodes of vomiting. Detailed information on 
patient demographics and complications and levels of seda-
tive drugs and vasopressors can be found in the supplementary 
information (Supplemental Digital Content 1, http://links.
lww.com/CCM/B945).
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Data were collected between 2 and 4 days (mean, 3.5 d) 
following primary SAH. Because of cardiovascular instability 
and unknown behavior of sodium nitrite in this population at 
that time, it was not possible to collect data sooner than day 4 
in patients 2 and 6. Seven of the study patients (50%) devel-
oped DCI as defined by consensus guidelines (20). This is in 
keeping with a higher incidence of DCI reported in previous 
studies of high-grade (WFNS grade, 3–5) SAH patients (25) 
(Table 1).
All patients were diagnosed with hydrocephalus and were 
treated with external ventricular drainage immediately at 
admission to the neurosurgical centre. There was no rebleed-
ing. All patients were treated with endovascular embolization. 
Three patients died (patients 2, 4, and 7), two from compli-
cations following severe DCI and one from cardiovascular 
instability. Three patients (patients 1, 5, and 14) developed 
sepsis secondary to chest infection, which were treated with IV 
antibiotics.
qEEG Results
Visual inspection of raw electroencephalographic data did 
not reveal any ictal or preictal activity in any of the recruited 
patients.
Spectrograms of the entire recording for two patients are 
shown in Figure 1. Figure 2 illustrates the raw data from each 
patient represented as an average of the five values before and 
during infusion, which are converted into a percentage change 
from baseline. Figure 3 demonstrates the percentage change 
from baseline ADR over time for the two groups.
Results from the linear regression model showed an 
increase in ADR from a mean of 0.033 (se = 0.008) to a 
mean of 0.055 (se = 0.010) in response to sodium nitrite 
in the no-DCI group (p < 0.0001) and a decrease in ADR 
from mean baseline of 0.056 (se = 0.010) to a mean of 0.050 
(se = 0.009) in response to sodium nitrite in the DCI group 
(p = 0.006). There was a trend for a higher baseline ADR in 
the DCI group than the no-DCI group (p = 0.072). There 
was no evidence of an effect of propofol, midazolam, age, or 
WFNS grade on the ADR response. Comparing the change 
in ADR for the DCI group with the change in ADR in the no- 
DCI group demonstrated that the estimated mean for 
the DCI group was 0.028 (se = 0.003) less than that of the 
no-DCI group (p < 0.0001).
The Bayesian model confirmed the results described above 
and revealed that the baseline ADR had a significant effect on 
the ADR response to the drug. More specifically, it showed 
TAbLE 1.  Demographics of Patients Recruited to the Study, Showing Age, World 
Federation of Neurosurgeons Grade, Aneurysm Location, and the Development of 
Delayed Cerebral Ischemia
Patient
Age (yr)/ 
Sex
World Federation  
of Neurosurgeons 
Grade
Aneurysm  
Location
DCI  
(Yes/No)
Day Post  
bleed of DCI  
Diagnosis
Study  
Day Post 
bleed
Modified Rankin 
Scale Score at  
3 mo
 1 55/female 5 Left PComm No N/A 2 1
 2 53/female 5 A1/A2 Yes 10 4 6
 3 52/female 4 AComm No N/A 2 0
 4 48/female 5 MCA Yes 5 2 6
 5 50/female 3 A1/A2 Yes 16 3 5
 6 44/male 5 AComm No N/A 4 2
 7 58/female 3 Right MCA Yes 7 2 6
 8 54/female 4 Right PComm No N/A 2 2
 9 56/female 3 Right PComm No N/A 2 1
10 41/female 3 Left PComm No N/A 2 1
11 47/female 4 Left A2 Yes 9 2 2
12 49/female 3 Right vertebral Yes 8 2 4
13 63/male 4 AComm No N/A 3 2
14 69/male 5 AComm Yes 5 3 4
A1/A2 = A1 and A2 segments of anterior communicating artery, AComm = anterior communicating artery, DCI = delayed cerebral ischemia, MCA = middle 
cerebral artery, N/A = not applicable, PComm = posterior communicating artery.
Modified Rankin Scale (mRS) scores are as follows: 0 = no symptoms at all; 1 = no significant disability despite symptoms, able to carry out all usual duties and 
activities; 2 = slight disability, unable to carry out all previous activities but able to look after own affairs without assistance; 3 = moderate disability, requiring 
some help, but able to walk without assistance; 4 = moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs 
without assistance; 5 = severe disability, bedridden, incontinent and requiring constant nursing care and attention; and 6 = dead.
Day of study and outcome in the form of the mRS are also included. In keeping with the known incidence of aneurysmal subarachnoid hemorrhage, the majority 
of patients are female.
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that in the no-DCI group, the baseline ADR increases by 0.273 
ADRbaseline , whereas in the DCI group, the baseline ADR 
decreases by 0 054 0 285. .− ADRbaseline  in response to the drug. 
This model therefore further clarified that the ADR response 
to the drug was significantly affected by whether the patient 
subsequently developed DCI.
Physiologic Data
In response to sodium nitrite infusion, there was a significant 
decrease (p = 0.026) in mean arterial pressure (MAP) from a 
mean of 87 mm Hg (sd, 13 mm Hg) to 84 mm Hg (sd, 13 mm 
Hg). There were no significant changes in MCAV, ICP, end-
tidal Co
2
, or end-tidal O
2
 values (Table 2).
DISCUSSION
This pilot study investigated the qEEG response to IV sodium 
nitrite as a potential way to predict the development of DCI in 
patients with severe SAH. Patients who did not develop DCI 
showed a strong increase in the ADR in response to sodium 
nitrite, whereas patients who went on to develop DCI showed 
a small decrease or no change in the ADR.
Our findings suggest mechanistic differences in the way 
the brain responds to increasing cerebral NO, depending on 
the severity of the injury. The no-DCI group responded as 
expected, demonstrating a move toward a less ischemic picture 
as demonstrated by increased ADR in response to NO reple-
tion. However, the opposite was seen in the DCI group.
There are several potential explanations for these findings. 
One possibility is that there may be more severe brain injury and 
greater cerebral NO pathway dysfunction in patients who subse-
quently develop DCI. The dose of sodium nitrite chosen may have 
been insufficient for eliciting a response in the electroencephalog-
raphy. A longer duration of infusion or a higher dose may have 
demonstrated different electroencephalographic changes.
A further possibility is that increased cerebral NO may 
selectively vasodilate in areas where there is less tissue damage, 
diverting blood away from the more ischemic areas, causing a 
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Figure 1. Single-channel spectrograms from a patient that did not 
develop delayed cerebral ischemia (DCI) (top) and from a patient who 
developed DCI (bottom).
Figure 2. Scatter plot showing the percentage change in alpha/delta 
frequency ratio (ADR) for each patient, grouped by the presence or 
absence of subsequent delayed cerebral ischemia (DCI). The horizontal 
bar represents the mean for each group. It can be seen that there is 
greater variability in the response to the drug in the group that did not 
develop DCI, suggesting that there may be a spectrum of neuronal 
damage that is unmasked by the drug, raising the possibility that 
there may be differing degrees of neuronal disruption after severe 
subarachnoid hemorrhage.
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Figure 3. Percentage change from baseline alpha/delta frequency ratio 
(ADR) over time, calculated by dividing the ADR at each time point by 
the baseline for the patients who subsequently did not develop delayed 
cerebral ischemia (DCI) (top) and for those who did develop DCI (bottom). 
Error bars represent the sem. The dashed vertical line represents the start 
of the sodium nitrite infusion.
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“steal” phenomenon. This would cause a deterioration in per-
fusion to injured areas and a move toward a more ischemic 
pattern on electroencephalography. It also implies loss of local 
autoregulation, already known to occur after severe SAH and 
which is linked to poor outcomes (26). In addition, delivering 
NO to areas of the brain with increased levels of free radicals 
may encourage the production of neurotoxic peroxynitrite, 
further contributing to cell damage (27).
It is important to note that the two groups of patients 
were indistinguishable at presentation in terms of clini-
cal severity (WFNS score), Fisher grade, or baseline ADR. 
Therefore, increasing cerebral NO unmasks cerebral neuronal 
and metabolic dysfunction that is otherwise not detectable. 
Electroencephalographic changes have been previously linked 
to the development of DCI but have required several days of 
recording (15, 28). Using a drug to probe electroencephalo-
graphic responses dynamically enabled the duration of record-
ing to be considerably shorter than previous studies (average of 
5 d; range 1–60 d) (29).
TCD and ICP recordings remained stable in response to 
sodium nitrite, confirming that the observed qEEG changes 
were not because of changes in global cerebral blood flow. The 
patients who developed DCI were not followed up with repeat 
TCD or other measurements outside routine clinical care to 
detect angiographic vasospasm, but this would be an interest-
ing addition to any future studies. The small drop in MAP is 
very unlikely to have clinical implications.
Limitations
The number of patients recruited was small, and there is 
risk of bias because of the unblinded nature of this study. A 
double-blinded and randomized validation study in a larger 
group of patients is necessary. As sodium nitrite was infused 
for only hour, it is possible that steady state might not have 
been achieved in all patients. Future studies might investigate 
longer recording durations and investigate the electroencepha-
lographic changes during the offset of sodium nitrite. It would 
also be important to investigate patients with a less severe 
degree of EBI by including WFNS grades 1 and 2 in future 
work.
Although there was no control group, comparing baseline 
to values collected during the infusion allowed each patient to 
act as their own control, minimizing the effects of metabolic 
alterations, ICP changes, or effects of sedation. Although seda-
tion will have affected the electroencephalographic pattern, 
it is unavoidable when studying this cohort of patients. The 
limited number of electroencephalographic electrodes hinders 
interpretation of spatial resolution, but fewer electroencepha-
lographic electrodes increase the practicability of using this 
method in an intensive care setting.
CONCLUSIONS
In conclusion, we have shown that a 1-hour infusion of IV 
sodium nitrite can induce measurable qEEG changes capable 
TAbLE 2. Mean Physiologic Values Pre Versus During Sodium Nitrite Infusion
Patient
Mean Arterial  
Pressure  
(mm Hg), Mean 
(sd); p = 0.02
End-Tidal  
O2 (kPa),  
Mean (sd);  
p = 0.2
Co2 (kPa),  
Mean (sd);  
p = 0.98 Arterial  
Co2 Values 
(kPa)
Middle Cerebral 
Artery Velocity  
Transcranial  
Doppler (cm/s),  
Mean (sd); p = 0.96
Intracranial  
Pressure  
(mm Hg),  
Mean (sd);  
p = 0.529
Pre During Pre During Pre During Pre During Pre During
 1 73 (3) 67 (1) 28 (2) 28 (2) 4.2 (0.4) 4.8 (0.1) 5.86 62 (10) 85 (3) N/R N/R
 2 80 (3) 77 (2) 48 (3) 50 (2) 3.8 (0.1) 3.7 (0.1) 5.59 51 (6) 46 (2) N/R N/R
 3 75 (2) 73 (1) 44 (2) 44 (2) 3.9 (0.1) 4.0 (0.0) 5.20 91 (2) 88 (2) 3 (1) 3 (1)
 4 75 (2) 73 (2) 44 (3) 45 (2) 3.8 (0.1) 3.95 (0.0) 4.87 91 (2) 89 (2) 3 (1) 3 (1)
 5 93 (3) 91 (6) 22 (1) 25 (9) 4.7 (0.0) 4.7 (0.3) 5.57 50 (3) 52 (6) 8 (2) 6 (3)
 6 81 (16) 86 (15) 33 (1) 33 (1) 4.9 (0.4) 4.8 (0.2) 5.35 55 (6) 69 (6) 7 (2) 7 (2)
 7 86 (11) 90 (5) N/R N/R N/R N/R 4.72 47 (2) 44 (3) N/R N/R
 8 78 (1) 75 (2) 30 (0) 29 (1) 5.8 (0.1) 5.7 (0.2) 5.06 108 (3) 103 (3) 20 (0) 21 (0)
 9 90 (1) 83 (3) 26 (2) 26 (2) 3.9 (0.1) 3.9 (0.1) 4.12 35 (2) 36 (5) 11 (0) 11 (0)
10 105 (5) 94 (5) 23 (2) 23 (2) 4.4 (0.5) 4.3 (0.5) 5.46 N/R N/R 13 (3) 12 (2)
11 88 (4) 82 (5) 23 (3) 23 (3) 4.1 (8.5) 4.8 (5.9) 4.93 93 (13) 97 (8) 9 (3) 6 (3)
12 79 (3) 75 (2) 25 (0) 25 (1) 3.4 (0.1) 3.5 (0.2) 4.04 43 (3) 45 (3) 9 (3) 12 (3)
13 118 (4) 114 (6) 31 (1) 34 (3) 3.4 (0.1) 3.5 (0.2) 5.66 70 (3) 69 (8) N/R N/R
14 92 (8) 92 (4) 54 (2) 55 (2) 4.1 (0.6) 3.6 (0.1) 4.75 50 (14) 36 (16) 7 (4) 6 (2)
Co2 = end-tidal carbon dioxide, N/R = not recorded.
p values represent the results of two-tailed t tests comparing pre versus during infusion values.
Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
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of discriminating which patients eventually develop DCI. 
Our findings emphasize the importance of EBI as a window 
of therapeutic opportunity to institute aggressive neuropro-
tective strategies. Measuring qEEG responses to an NO donor, 
such as sodium nitrite, might also represent a potentially use-
ful method for patient stratification, which may be useful in 
clinical trials. Therefore, with further validation, these find-
ings demonstrate the potential to develop an electroencepha-
lography-based, patient-specific tool to predict DCI.
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